Advanced Solid Tumors
Conditions
Brief summary
A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.
Detailed description
This is an open-label, dose-escalation and dose-expansion, multiple-dose, phase 1 study evaluating HF50 monotherapy in participants with advanced solid tumors. HF50 is an innovative liposome-encapsulated T-cell engager designed to redirect T-cells to tumor cells by presenting both tumor-associated antigen (e.g., HER2) and CD3 targeting moieties on the liposome surface. Simultaneously, HF50 delivers an encapsulated TLR7/8 agonist to activate innate immunity and remodel the tumor immune microenvironment, creating a synergistic anti-tumor immune response.The primary objective is to evaluate the safety and tolerability of HF50 and to determine the recommended Phase 2 dose (RP2D). HF50 will be administered as an intravenous (IV) infusion. The study will also assess the pharmacokinetic (PK) profile, immunogenicity, and preliminary anti-tumor activity of HF50. Additionally, the study will explore the impact of HF50 on the immune microenvironment and changes in peripheral blood cytokines and immune cells to better understand its biological effects.
Interventions
DRUGHF50
HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism.
Sponsors
HighField Biopharmaceuticals Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Voluntary participation: Capable of giving signed informed consent and able to comply with all study-related procedures. * Age: Adults \>= 18 years of age at the time of signing informed consent; male or female. * Disease Status: Participants with histologically or cytologically confirmed advanced solid tumors that are unresectable or metastatic, who have failed or are intolerant to standard therapies, or for whom no effective therapy currently exists. Examples include HER2-expressing gynecological tumors and recurrent ovarian clear cell carcinoma after failure of platinum-based chemotherapy. * Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1. * Life Expectancy: Anticipated survival of no less than 6 months. * Measurable Disease: At least one measurable lesion according to RECIST v1.1 definitions. * Organ and Bone Marrow Function: Bone Marrow Reserve: Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L, lymphocyte count \>= 1.0 x 10\^9/L, platelet count \>= 90 x 10\^9/L, and hemoglobin \>= 9.0 g/dL (no blood transfusion or hematopoietic stimulators within 14 days). Coagulation Function: Activated partial thromboplastin time (APTT) \<= 1.5 x ULN, and International Normalized Ratio (INR) \<= 1.5. Liver Function: Total bilirubin (TBIL) \<= 1.5 x ULN, and ALT and AST \<= 2.5 x ULN. For participants with liver metastases: ALT and AST \<= 5 x ULN, and TBIL \<= 3 x ULN. Renal Function: Creatinine clearance \>= 50 mL/min (calculated using the Cockcroft-Gault formula). * Contraception: Participants of reproductive potential (including males) must agree to use effective contraception from study entry through 6 months after the last dose. Female participants of childbearing potential must have a negative serum pregnancy test during screening and prior to the first dose.
Exclusion criteria
* Autoimmune Disease: Any active autoimmune disease or history of autoimmune disease deemed unsuitable by the investigator. Exceptions include skin conditions not requiring systemic treatment (e.g., eczema \< 10% of body surface area, vitiligo, psoriasis, alopecia) and resolved childhood asthma. * Corticosteroids/Immunosuppressants: Current use of immunosuppressants or systemic corticosteroids (\> 10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose. Topical steroid use is permitted. * Prior Anti-tumor Therapy: Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 2 weeks prior to dosing (4 weeks for nitrosoureas or mitomycin C); or other therapies (endocrine therapy, TCM, localized palliative radiotherapy) within 2 weeks. * CNS Metastasis: Clinically symptomatic brain or meningeal metastases. Participants with treated brain metastases are eligible if radiographic stability is maintained for \>= 28 days, systemic steroids have been discontinued for \> 14 days, and the participant is asymptomatic. * Toxicity Recovery: Failure to recover from all adverse events of prior therapies to \<= Grade 1 (NCI CTCAE v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement. * Cardiovascular History: Including thromboembolic events within 3 months; NYHA Class III to IV congestive heart failure; acute coronary syndrome, aortic dissection, stroke, or other Grade \>= 3 cardiovascular events within 6 months; or uncontrolled hypertension (SBP \> 160 mmHg or DBP \> 100 mmHg). * Infection: Active infection or unexplained fever \> 38.5 degrees C within 1 week prior to the first dose (tumor-related fever is permitted per investigator judgment). * Viral Infection: HIV infection, active HBV (HBV DNA \> ULN), or active HCV (HCV RNA \> ULN). * Gastrointestinal Symptoms: Significant digestive system symptoms or other factors requiring intervention within 4 weeks prior to the first dose. * Pregnancy/Lactation: Female participants who are pregnant or breastfeeding. * Other: Any other serious systemic disease or reason that, in the investigator's opinion, makes the participant unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Dose Limiting Toxicities (DLT) | 28 days after the first dose (C1D1) for each dose cohort. | The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD). |
| Incidence of Adverse Events (AEs) | From first dose to 28 days after the last dose. | The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0 |
| Recommended Phase II Dose (RP2D) of HF50 | At the end of dose escalation (assessed up to 1 year) | RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to 2 years | Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria. |
| Duration of Response (DOR) | Up to 2 years | Time from the first documented response (CR or PR) to disease progression or death. |
| Disease Control Rate (DCR) | Up to 2 years | Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1. |
| Progression-Free Survival (PFS) | Up to 2 years | Time from the first dose to disease progression or death. |
| Overall Survival (OS) | Up to 2 years | Time from the first dose to death from any cause. |
| Pharmacokinetic Parameter - Cmax | Up to 2 years | Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing. |
| Pharmacokinetic Parameter - Tmax | Up to 2 years | Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing. |
| Pharmacokinetic Parameter - AUC (Area Under the Curve) | Up to 2 years | AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50. |
| Pharmacokinetic Parameter - Half-life (t1/2) | Up to 2 years | The terminal elimination half-life (t1/2) of HF50 will be calculated. |
Countries
China
Contacts
CONTACTxun Wang
Outcome results
None listed